Gossamer Bio (NASDAQ:GOSS) Given Outperform Rating at Wedbush

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a report released on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 175.86% from the company’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research note on Thursday, January 30th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Up 11.5 %

Shares of GOSS opened at $1.45 on Friday. The firm has a market capitalization of $328.58 million, a P/E ratio of -4.53 and a beta of 1.86. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a fifty day moving average price of $1.13 and a 200-day moving average price of $0.97.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analysts’ expectations of $7.02 million. Equities research analysts expect that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently made changes to their positions in the company. Octagon Capital Advisors LP raised its holdings in shares of Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after acquiring an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after purchasing an additional 3,041,058 shares in the last quarter. Silverarc Capital Management LLC raised its holdings in Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock worth $5,583,000 after purchasing an additional 526,495 shares in the last quarter. Monaco Asset Management SAM raised its holdings in Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Gossamer Bio by 14.6% in the fourth quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock worth $3,244,000 after purchasing an additional 457,179 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.